Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy

Karizak, Ashkan Zare; Salmasi, Zahra; Gheibihayat, Seyed Mohammad; Asadi, Mohammad; Ghasemi, Younes; Tajbakhsh, Amir; Savardashtaki, Amir

doi:10.1007/s00432-022-04452-w

Cited by 6 publications

(3 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The phagocytic clearance of dying cells profoundly influences innate and adaptive immune system responses. Disposing of ACs via efferocytosis prevents necrosis and the consequent inflammation generated by releasing the intracellular contents 19–24 …”

Section: Efferocytosismentioning

confidence: 99%

See 1 more Smart Citation

The role of efferocytosis and transplant rejection: Strategies in promoting transplantation tolerance using apoptotic cell therapy and/or synthetic particles

Vafadar,

Vosough,

Jahromi

et al. 2023

Cell Biochemistry & Function

Self Cite

View full text Add to dashboard Cite

Recently, efforts have been made to recognize the precise reason(s) for transplant failure and the process of rejection utilizing the molecular signature. Most transplant recipients do not appreciate the unknown length of survival of allogeneic grafts with the existing standard of care. Two noteworthy immunological pathways occur during allogeneic transplant rejection. A nonspecific innate immune response predominates in the early stages of the immune reaction, and allogeneic antigens initiate a donor‐specific adaptive reaction. Though the adaptive response is the major cause of allograft rejection, earlier pro‐inflammatory responses that are part of the innate immune response are also regarded as significant in graft loss. The onset of the innate and adaptive immune response causes chronic and acute transplant rejection. Currently employed immunosuppressive medications have shown little or no influence on chronic rejection and, as a result, on overall long‐term transplant survival. Furthermore, long‐term pharmaceutical immunosuppression is associated with side effects, toxicity, and an increased risk of developing diseases, both infectious and metabolic. As a result, there is a need for the development of innovative donor‐specific immunosuppressive medications to regulate the allorecognition pathways that induce graft loss and to reduce the side effects of immunosuppression. Efferocytosis is an immunomodulatory mechanism with fast and efficient clearance of apoptotic cells (ACs). As such, AC therapy strategies have been suggested to limit transplant‐related sequelae. Efferocytosis‐based medicines/treatments can also decrease the use of immunosuppressive drugs and have no detrimental side effects. Thus, this review aims to investigate the impact of efferocytosis on transplant rejection/tolerance and identify approaches using AC clearance to increase transplant viability.

show abstract

Section: Efferocytosismentioning

confidence: 99%

“…Disposing of ACs via efferocytosis prevents necrosis and the consequent inflammation generated by releasing the intracellular contents. [19][20][21][22][23][24] Thus, in complicated multicellular living organisms, efferocytosis is essential for development, growth, inflammation resolution, and tissue homeostasis. [25][26][27]…”

Section: Efferocytosismentioning

confidence: 99%

The role of efferocytosis and transplant rejection: Strategies in promoting transplantation tolerance using apoptotic cell therapy and/or synthetic particles

Vafadar,

Vosough,

Jahromi

et al. 2023

Cell Biochemistry & Function

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, tumor cells overexpress immune checkpoint molecules that subsequently release “don’t eat me” signals to immune cells. In this way, the checkpoint molecules establish an immune-suppressive TME that facilitates evasion of immune surveillance [ 14 , 15 ]. It is noteworthy that the initial findings of the TOPAZ-1 trial indicate a significant improvement in overall survival (OS) and progression-free survival (PFS) for patients with advanced CCA when the checkpoint inhibitor, durvalumab is added to gemcitabine-cisplatin (GemCis).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes

Li,

Bie,

Chen

et al. 2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a highly aggressive type of adenocarcinoma distinguished by its invasiveness. Depending on specific anatomical positioning within the biliary tree, CCA can be categorized into intrahepatic CCA (ICCA), perihilar CCA (pCCA) and distal CCA (dCCA). In recent years, there has been a significant increase in the global prevalence of CCA. Unfortunately, many CCA patients are diagnosed at an advanced stage, which makes surgical resection impossible. Although systemic chemotherapy is frequently used as the primary treatment for advanced or recurrent CCA, its effectiveness is relatively low. Therefore, immunotherapy has emerged as a promising avenue for advancing cancer treatment research. CCA exhibits a complex immune environment within the stromal tumor microenvironment (TME), comprising a multifaceted immune landscape and a tumor-reactive stroma. A deeper understanding of this complex TME is indispensable for identifying potential therapeutic targets. Thus, targeting tumor immune microenvironment holds promise as an effective therapeutic strategy.

show abstract

MMP2 enzyme-responsive extracellular vesicles as dual-targeted carriers to promote the phagocytosis of macrophages

Zhong,

Zhang,

Yue

et al. 2025

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy

Cited by 6 publications

References 116 publications

The role of efferocytosis and transplant rejection: Strategies in promoting transplantation tolerance using apoptotic cell therapy and/or synthetic particles

The role of efferocytosis and transplant rejection: Strategies in promoting transplantation tolerance using apoptotic cell therapy and/or synthetic particles

Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes

MMP2 enzyme-responsive extracellular vesicles as dual-targeted carriers to promote the phagocytosis of macrophages

Contact Info

Product

Resources

About